• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BJOG: an international journal of obstetrics and gynaecology >The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
【24h】

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

机译：四价人乳头瘤病毒疫苗（6/11/16/18）在英国的流行病学和经济影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts. DESIGN: Cost-utility analysis. SETTING: UK. POPULATION: Female and male UK population 12 years or older. METHODS: We adapted a previously developed multi-HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch-up vaccination at ages 12-14, 12-17 and 12-24 years. MAIN OUTCOMES MEASURES: Costs, cases avoided, incremental cost per quality-adjusted life year (QALY). RESULTS: The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18-related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccinationat age 12 years combined with a 12- to 24-year-old catch-up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2/3, CIN1 and genital warts by 5800, 146 000, 28 000, and 1.1 million respectively. Over 100 years, the incremental cost-effectiveness ratios across all strategies ranged from pound5882 to pound11,412 per QALY gained. CONCLUSION: In the UK, a quadrivalent HPV vaccination programme that includes a catch-up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost-effective.
机译：目的：评估预防性四价人类乳头瘤病毒（HPV）（6/11/16/18）疫苗对预防宫颈癌，宫颈上皮内瘤样变2和3（CIN2 / 3），CIN1和生殖器的潜在流行病学和经济影响疣。设计：成本效用分析。地点：英国。人口：英国12岁或以上的男女人口。方法：我们采用了以前开发的多HPV型动态变速箱，以比较四种女性疫苗接种策略，12岁时的常规疫苗接种，12岁时的常规疫苗接种以及12-14岁，12-17岁的临时追赶疫苗接种和12-24岁。主要结果指标：成本，避免的病例，每质量调整生命年（QALY）的增量成本。结果：该模型预测，在100年时，每种疫苗接种策略均可使女性与HPV 6/11/16/18相关的子宫颈癌，CIN2 / 3，CIN1和尖锐湿疣的数量减少86、85、79和89 ％ 分别。在过去的25年中，最有效的策略是在12岁时进行常规疫苗接种并结合12至24岁的追赶计划，从而将宫颈癌，CIN2 / 3，CIN1和尖锐湿疣的累计病例数减少5800 ，分别为146 000、28 000和110万。在过去的100年中，所有策略的每增加一个QALY所产生的增量成本效益比从5882英镑到11,412英镑不等。结论：在英国，包括追赶策略在内的四价HPV疫苗接种计划可以以通常认为具有成本效益的范围内的每QALY成本降低宫颈癌，CIN和生殖器疣的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号